{"data":{"id":"us/21-cfr-201.50","jurisdiction":"us","citation":"21 CFR 201.50","heading":"Statement of identity.","body":"(a) The label of prescription and insulin-containing drugs in package form shall bear as one of its principal features a statement of the identity of the drug.\n(b) Such statement of identity shall be in terms of the established name of the drug. In the case of a prescription drug that is a mixture and that has no established name, the requirement for statement of identity shall be deemed to be satisfied by a listing of the quantitative ingredient information as prescribed by § 201.10.\n(c) The statement of identity of a prescription drug shall also comply with the placement, size and prominence requirements of § 201.10.","path":["Title 21—Food and Drugs","CHAPTER I—FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN SERVICES","SUBCHAPTER C—DRUGS: GENERAL","PART 201—LABELING","Subpart B—Labeling Requirements for Prescription Drugs and/or Insulin"],"source_url":"https://www.ecfr.gov/api/versioner/v1/full/2026-08-25/title-21.xml","current_through":"2026-08-25","vintage":"","retrieved_at":"2026-08-27T02:24:47Z","sha256":"2a520379670a8b07da8a5b31054ed0a8c38c8e7491a23e72677c89b1051c6a24","source_id":"us-cfr","stale":true,"prev":"us/21-cfr-201.26","next":"us/21-cfr-201.51"},"notice":"GroundRules: Original legal text. Not legal advice."}